Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diasorin SpACHIX:DIAM 78 Intrinsic Value: Projected FCF is €80.65 as of Aug. 20, 2026, which is 100% below its 10-year median of 1.86. GuruFocus rates CHIX:DIAM with a GF Score™ of 78/100 and a GF Value™ of €88.86 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 104 Medical Diagnostics & Research companies, Diasorin SpA ranks better than 72.12% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-08-20), Diasorin SpA's Intrinsic Value: Projected FCF is €80.65. The stock price of Diasorin SpA is €74.19. Therefore, Diasorin SpA's Price-to-Intrinsic-Value-Projected-FCF of today is 0.9.
The historical rank and industry rank for Diasorin SpA's Intrinsic Value: Projected FCF or its related term are showing as below:
CHIX:DIAm'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.66 Med: 1.86 Max: 3.32
Current: 0.92
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Diasorin SpA was 3.32. The lowest was 0.66. And the median was 1.86.
CHIX:DIAm's Price-to-Projected-FCF is ranked better than 72.12% of 104
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.52
vs CHIX:DIAm: 0.92
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Diasorin SpA's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
74.19
/
80.52557912876
=
0.92
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diasorin SpA Intrinsic Value: Projected FCF Related Terms
Diasorin SpA Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DIAM vs TMO, DHR, IDXX: Intrinsic Value: Projected FCF Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA Price-to-Projected-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of €80.65 mean?
Diasorin SpA (CHIX:DIAM) has a Intrinsic Value: Projected FCF of €80.65 as of Aug. 20, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Diasorin SpA and its competitors. This is 4236% above median its historical median of 1.86. Over the past decade, Diasorin SpA's Intrinsic Value: Projected FCF has ranged from 0.66 to 3.32. According to the industry distribution chart, Diasorin SpA ranks #29 out of 104 companies in the Medical Diagnostics & Research industry, placing it in the top 27.9%.
Is Diasorin SpA's Intrinsic Value: Projected FCF too high?
Diasorin SpA's current Intrinsic Value: Projected FCF of €80.65 is 4236% above median its 10-year median of 1.86. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 3.32. Based on the distribution chart, Diasorin SpA ranks #29 out of 104 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diasorin SpA has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Intrinsic Value: Projected FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #29 out of 104 companies for Intrinsic Value: Projected FCF. This puts Diasorin SpA in the upper half of its industry. The industry median Intrinsic Value: Projected FCF is 1.52. Historically, Diasorin SpA's own Intrinsic Value: Projected FCF has ranged from 0.66 to 3.32 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Diagnostics & Research company?
The median Intrinsic Value: Projected FCF among Medical Diagnostics & Research companies is 1.52, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Diasorin SpA and its competitors. For the Medical Diagnostics & Research industry, the median Intrinsic Value: Projected FCF is 1.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diasorin SpA's current Intrinsic Value: Projected FCF is €80.65, which is 4236% above median its own 10-year median of 1.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (CHIX:DIAM) is currently considered Modestly Undervalued. The stock's GF Value™ is €88.86, compared to a current price of €74.19 — trading 16.5% below its estimated fair value. The current Intrinsic Value: Projected FCF is €80.65, which is 4236% above median its 10-year median of 1.86. Diasorin SpA's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Diasorin SpA (CHIX:DIAM), the current Intrinsic Value: Projected FCF is €80.65 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (CHIX:DIAM) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €74.19 is trading 16.5% below its estimated GF Value™ of €88.86.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for CHIX:DIAM:
Intrinsic Value: Projected FCF: €80.65 (4236% above median its 10-year median of 1.86)
GF Value™: €88.86 vs. price of €74.19 (16.5% below fair value)
No single metric tells the full story. See the CHIX:DIAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
78GF Score
Get the complete analysis for CHIX:DIAM
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIAM has been successfully added to your 
